公开(公告)号：JP2004043507A

公开(公告)日：2004-02-12

申请号：JP2003373712

申请日：2003-10-31

Applicant: La Jolla Cancer Research Foundation ,  ラ ホヤ キャンサー リサーチ ファウンデーションLa Jolla Cancer Research Foundation

Inventor： RUOSLAHTI ERKKI I ,  BORDER WAYNE A

IPC: A61K45/00 ,  A61K38/00 ,  A61K38/17 ,  A61K38/18 ,  A61K38/22 ,  A61K38/39 ,  A61K39/395 ,  A61P3/08 ,  A61P3/10 ,  A61P9/00 ,  A61P9/10 ,  A61P11/00 ,  A61P13/02 ,  A61P13/12 ,  A61P15/00 ,  A61P17/02 ,  A61P35/00 ,  A61P43/00 ,  C07K16/22

CPC classification number: A61K38/1709 ,  A61K38/1858 ,  A61K38/39 ,  C07K16/22

Abstract: PROBLEM TO BE SOLVED: To determine a factor for controlling harmful accumulation of matrix components in a pathological stage such as a kidney disease, and control a factor for preventing, restricting or curing pathological conditions including unsuitable accumulation of a matrix. SOLUTION: A method for inhibiting the accumulation of extracellular matrix components in a tissue by bringing the tissue into contact with an agent to control the activity of the transforming growth factor β (TGF-β) is offered. The agent can be, for example, an anti-TGF-β antibody, a platelet-derived growth factor (PDGF), a peptide containing Arg-Gly-Asp, a decorin or a biglycan with the similar function. COPYRIGHT: (C)2004,JPO

Abstract translation: 要解决的问题：确定在肾病等病理阶段中控制基质成分的有害积累的因素，并控制预防，限制或治愈包括不适合的基质积累的病理状况的因素。 提供了一种通过使组织与药剂接触以控制转化生长因子β（TGF-β）的活性来抑制组织中细胞外基质成分积累的方法。 试剂可以是例如抗TGF-β抗体，血小板衍生生长因子（PDGF），含有Arg-Gly-Asp的肽，具有相似功能的核心蛋白聚糖或双糖缩蛋白聚糖。 版权所有（C）2004，JPO

公开(公告)号：JP2004159664A

公开(公告)日：2004-06-10

申请号：JP2004002452

申请日：2004-01-07

Applicant: La Jolla Cancer Research Foundation ,  Sri Internatl ,  エスアールアイ インターナショナルSri International ,  ラ ホヤ キャンサー リサーチ ファウンデーションLa Jolla Cancer Research Foundation

Inventor： PHAHL MAGNUS ,  ZHANG XIAO-KUN ,  LEHMANN JURGEN M ,  DAWSON MARCIA I ,  CAMERON JAMES F ,  HOBBS PETER D ,  JONG LING

IPC: G01N33/50 ,  A61K31/19 ,  A61K31/335 ,  A61K31/357 ,  A61K31/36 ,  A61K31/38 ,  A61K31/381 ,  A61K31/385 ,  A61K31/39 ,  A61P3/00 ,  A61P3/02 ,  A61P5/12 ,  A61P17/00 ,  A61P31/12 ,  A61P35/00 ,  A61P35/02 ,  A61P37/00 ,  A61P43/00 ,  C07C63/49 ,  C07C63/66 ,  C07C65/36 ,  C07C69/738 ,  C07C69/76 ,  C07C233/64 ,  C07D311/58 ,  C07D317/30 ,  C07D319/06 ,  C07D327/04 ,  C07D333/22 ,  C07D333/38 ,  C07D339/06 ,  C07D339/08 ,  C07D409/04 ,  C07K14/705 ,  C12N15/09 ,  G01N33/15 ,  G01N33/53 ,  G01N33/566 ,  G01N33/68 ,  G01N33/74

CPC classification number: C07D409/04 ,  A61K31/19 ,  A61K31/36 ,  C07C63/49 ,  C07C63/66 ,  C07C69/738 ,  C07C69/76 ,  C07D317/30 ,  C07D319/06 ,  C07D327/04 ,  C07D333/38 ,  C07D339/06 ,  C07D339/08 ,  C07K14/70567 ,  G01N33/6875 ,  G01N33/74 ,  G01N2500/00

Abstract: PROBLEM TO BE SOLVED: To provide a method of screening a substance for an ability to effect the formation of a retinoid X receptor homodimer comprising combining the substance and a solution containing the retinoid X receptor and determining the presence of homodimer formation. SOLUTION: The method of screening a substance for an ability to affect the formation of the retinoid X receptor homodimer, comprises processes for combining the substance and the solution containing the retinoid X receptor, determining the presence of homodimer formation and determining the presence of the homodimer by detecting activation of transcription through the retinoid X receptor homodimer. COPYRIGHT: (C)2004,JPO

公开(公告)号：JP2003034651A

公开(公告)日：2003-02-07

申请号：JP2002158174

申请日：2002-05-30

Applicant: La Jolla Cancer Research Foundation ,  ラ ホヤ キャンサー リサーチ ファウンデーション

Inventor： RUOSLAHTI ERKKI I ,  YAMAGUCHI YU

IPC: C12N15/09 ,  A61K38/00 ,  A61P9/10 ,  A61P13/02 ,  A61P13/12 ,  A61P15/00 ,  A61P19/02 ,  A61P29/00 ,  A61P35/00 ,  A61P43/00 ,  C07K1/22 ,  C07K14/00 ,  C07K14/47 ,  C07K14/50 ,  C12N5/00 ,  C12N5/02 ,  C12N5/06 ,  C12N5/10 ,  C12N15/12 ,  C12P21/00 ,  C12P21/02 ,  C12R1/91

CPC classification number: C07K14/4725 ,  A61K38/00 ,  C07K2319/00

Abstract: PROBLEM TO BE SOLVED: To provide a composition of drug which gives effects to type and/or amount of ingredients of extracellular matrix.
SOLUTION: The composition for formulating the drug which gives effect to type and/or amount of ingredients of extracellular matrix, containing substantially refined recombinant Decholin, wherein Decholin is selected from the group consisting of a natural composition of Decholin and its modified product having activity for inhibiting cellular proliferation, in which said refined recombinant Decholin without substantially contain impurities relating to the refining process, and the resultant refined product having the activity for inhibiting cellular proliferation.
COPYRIGHT: (C)2003,JPO

Abstract translation: 要解决的问题：提供对细胞外基质的成分的类型和/或量的影响的药物组合物。 解决方案：用于配制药物的组合物，其产生含有基本上精制的重组癸醇的细胞外基质的成分的类型和/或量的量，其中十氢化萘选自天然组合物，其具有活性的 抑制细胞增殖，其中所述精制的重组癸醇基本上不含有与精制方法有关的杂质，以及所得精制产物具有抑制细胞增殖的活性。

公开(公告)号：US20030069201A1

公开(公告)日：2003-04-10

申请号：US10285853

申请日：2002-11-01

Applicant: La Jolla Cancer Research Foundation

Inventor： John C. Reed

IPC: A61K048/00 ,  A61K038/57

CPC classification number: A01K67/0275 ,  A01K67/0271 ,  A01K2217/05 ,  A01K2227/105 ,  A01K2267/01 ,  A01K2267/025 ,  A01K2267/03 ,  A01K2267/0318 ,  A61K35/39 ,  A61K38/00 ,  C07K14/82 ,  C07K16/00 ,  C12N15/8509 ,  C12N2840/20 ,  C12N2840/203

Abstract: The invention provides a method of treating a disease or pathological condition resulting in apoptotic cell death. The method includes increasing the activity of Bcl-2 in cells affected by the disease or pathological condition. Diseases or pathological conditions can include, for example, neurodegenerative diseases, cancer and viral infections. Also provided is a method of prolonging the in vivo survival of transplanted cells for the treatment of a disease or pathological condition. The method includes increasing the activity of Bcl-2 in a population of cells and transplanting the population of cells having increased Bcl-2 activity into a subject. Diseases or pathological conditions can include, for example, neurodegenerative diseases, cancer and viral infections. A method to enhance the sensitivity of malignant cells to therapy is provided that includes decreasing the activity of Bcl-2 in the malignant cells. Methods to identify compounds that alter apoptotic cell death and to enhance monoclonal antibody production are also provided by the invention disclosed herein.

Abstract translation: 本发明提供了治疗导致凋亡性细胞死亡的疾病或病理状况的方法。 该方法包括增加Bcl-2在受疾病或病理状况影响的细胞中的活性。 疾病或病理状况可包括例如神经变性疾病，癌症和病毒感染。 还提供了延长移植细胞的体内存活以治疗疾病或病理状况的方法。 该方法包括增加细胞群中Bcl-2的活性，并将具有增加的Bcl-2活性的细胞群体移植到受试者中。 疾病或病理状况可包括例如神经变性疾病，癌症和病毒感染。 提供了增强恶性细胞对治疗的敏感性的方法，其包括降低恶性细胞中Bcl-2的活性。 鉴定化合物的方法来鉴定改变凋亡细胞死亡和增强单克隆抗体产生的化合物也由本文公开的本发明提供。

公开(公告)号：US20020028913A1

公开(公告)日：2002-03-07

申请号：US09892071

申请日：2001-06-26

Applicant: La Jolla Cancer Research Foundation

Inventor： Michael D. Pierschbacher ,  Erkki I. Ruoslahti

IPC: C07K005/08

CPC classification number: C07K7/06 ,  A61K38/00 ,  C07K7/08 ,  C07K7/50 ,  C07K7/64 ,  C07K14/47 ,  C07K14/78

Abstract: Novel synthetic Arg-Gly-Asp containing peptides which have high affinity and specificity for their receptors by virtue of restrictions on their stereochemical conformation. Such restrictions can be provided by cyclization, by inclusion into a constraining conformational structure such as a helix, by providing an additional chemical structure such as an amide or an enantiomer of a naturally occurring amino acid, or by other methods. In particular, there are provided cyclic peptides having increased affinity and selectivity for the certain receptors over that of linear, Arg-Gly-Asp-containing synthetic peptides.

Abstract translation: 新型合成的含有Arg-Gly-Asp的肽，由于其立体化学构象的限制，对其受体具有高亲和力和特异性。 通过提供另外的化学结构例如天然存在的氨基酸的酰胺或对映异构体，或通过其它方法，可以通过环化，包含在约束构象结构如螺旋中来提供这种限制。 特别地，提供的环肽对某些受体的亲和力和选择性高于线性的含Arg-Gly-Asp的合成肽。

公开(公告)号：US20020009726A1

公开(公告)日：2002-01-24

申请号：US09757041

申请日：2001-01-09

Applicant: La Jolla Cancer Research Foundation

Inventor： John C. Reed ,  Takaaki Sato

IPC: C12Q001/68 ,  G01N033/574 ,  C07H021/04 ,  C12P021/02 ,  C12N005/06

CPC classification number: C07K14/47 ,  A61K38/00 ,  A61K48/00 ,  C07K14/70578 ,  C07K16/28

Abstract: The present invention provides a mammalian CD40-associated protein (CAP), a nucleic acid molecule encoding the CAP and antibodies specific for the CAP. The invention further provides a substantially purified human CAP-1 and a nucleic acid molecule encoding human CAP-1. The invention also provides screening assays for identifying an agent that effectively alters the association of a CAP with a second molecule, which can bind to the CAP. In addition, the invention provides methods for identify a CAP agonist or CAP antagonist that can increase or decrease, respectively, the level of expression of the CAP in a cell. Such an effective agent, agonist or antagonist can modulate a function of a cell such as a humoral immune response or cell growth. The invention also provides methods of detecting a CAP in a sample by detecting the CAP or a nucleic acid molecule encoding the CAP. Such methods can be used to diagnose a pathology that is characterized by an increased or decreased level of a CAP in a cell.

Abstract translation: 本发明提供哺乳动物CD40相关蛋白（CAP），编码CAP的核酸分子和对CAP特异的抗体。 本发明还提供了基本上纯化的人CAP-1和编码人CAP-1的核酸分子。 本发明还提供用于鉴定有效改变CAP与可与CAP结合的第二分子缔合的试剂的筛选试验。 此外，本发明提供了鉴定CAP激动剂或CAP拮抗剂的方法，其可分别增加或减少CAP在细胞中的表达水平。 这种有效的药剂，激动剂或拮抗剂可以调节细胞的功能，例如体液免疫应答或细胞生长。 本发明还提供了通过检测CAP或编码CAP的核酸分子来检测样品中CAP的方法。 这样的方法可用于诊断以细胞中CAP增加或降低水平为特征的病理学。

公开(公告)号：US20030216295A1

公开(公告)日：2003-11-20

申请号：US10325606

申请日：2002-12-20

Applicant: La Jolla Cancer Research Foundation

Inventor： Minoru Fukuda ,  Ritsuko Sawada ,  Shigeru Tsuboi

IPC: A61K038/14 ,  C07H021/04 ,  C07K009/00 ,  C07K016/18 ,  C12P021/02 ,  C12N005/06

CPC classification number: C07K14/705 ,  A61K38/00 ,  C07K14/47

Abstract: The present invention provides antagonists to cell adhesion useful in controlling the negative effects of inflammation, and the metastasis of cancer cells. These antagonists are ligands to E-selectin containing the sialyl Lex structure, including sialyl Lex glycoproteins, sialyl Lex glycolipids, and sialyl Lex oligsaccharides, and other related sialyl Lex-containing molecules capable of inhibiting E-selectin mediated cell adhesion to endothelial cells. The present invention also provides antibodies against sialyl Lex determinants capable of interrupting E-selectin mediated cell adhesion, which are also considered antagonists according to the present invention. The present invention also provides methods of using the antagonists of the present invention to reduce inflammation, and methods to inhibit the process of metastasis by carcinogenic cells. The present invention-also provides nucleic acid molecules encoding the glycoprotein antagonists of the present invention, in particular soluble chimeric leukosialin, and vectors capable of expressing these nucleic acid molecules, as well as cells capable of producing sialyl Lex positive recombinant glycoproteins. The present invention further provides a method of determining metastatic potential by comparing the efficiency of E-selectin-mediated adhesion of cell samples. In addition the present invention provides a method of producing a preferred antagonist of the present invention, sialyl Lex positive glycoproteins, in particular, sialy Lex positive chimeric leukosialin.

Abstract translation: 本发明提供了可用于控制炎症的负面作用和癌细胞转移的细胞粘附的拮抗剂。 这些拮抗剂是含有唾液酸Lex结构的E-选择蛋白的配体，包括唾液酸Lex糖蛋白，唾液酸Lex糖脂和唾液酸Le x低聚糖以及其它相关的唾液酸含Lex 能够抑制E-选择蛋白介导的细胞粘附于内皮细胞的分子。 本发明还提供能够阻断E-选择素介导的细胞粘附的唾液酸Le x决定簇的抗体，其也被认为是根据本发明的拮抗剂。 本发明还提供了使用本发明的拮抗剂来减少炎症的方法，以及抑制致癌细胞转移过程的方法。 本发明还提供编码本发明的糖蛋白拮抗剂，特别是可溶性嵌合白血球蛋白的核酸分子，以及能够表达这些核酸分子的载体以及能够产生唾液酸Lex阳性重组糖蛋白的细胞。 本发明还提供了通过比较E-选择蛋白介导的细胞样品粘附的效率来确定转移潜能的方法。 此外，本发明提供了制备本发明优选的拮抗剂，唾液酸Le x阳性糖蛋白，特别是唾液酸Le x阳性嵌合白血球蛋白的方法。

公开(公告)号：US20030143733A1

公开(公告)日：2003-07-31

申请号：US10313928

申请日：2002-12-06

Applicant: La Jolla Cancer Research Foundation

Inventor： Erkki I. Ruoslahti ,  Michael D. Pierschbacher

IPC: A61K038/00 ,  C12N005/02

CPC classification number: A61K38/08 ,  A61K38/07 ,  A61K38/39 ,  A61L27/227

Abstract: The peptide X-Arg-Gly-Asp-R-Y wherein X is H or at least one amino acid and Y is OH or at least one amino acid, and R is an amino acid selected from Thr or Cys, or other amino acid, having the same cell-attachment activity as fibronectin and the peptide X-Arg-Gly-Asp-Ser-Y, wherein X and Y, having said activity are disclosed.

Abstract translation: 肽X-Arg-Gly-Asp-RY，其中X是H或至少一个氨基酸，Y是OH或至少一个氨基酸，R是选自Thr或Cys的氨基酸或其它氨基酸，其具有 具有与纤连蛋白相同的细胞附着活性和肽X-Arg-Gly-Asp-Ser-Y，其中X和Y具有所述活性。

公开(公告)号：AU639302B2

公开(公告)日：1993-07-22

申请号：AU7175991

申请日：1991-01-02

Applicant: LA JOLLA CANCER RESEARCH FOUNDATION

Inventor： ERKKI I. RUOSLAHTI ,  GUIDO TARONE ,  FILIPPO G GIANCOTTI ,  BRUCE E VOGEL

IPC: C07K14/435 ,  A61K38/00 ,  C07K1/16 ,  C07K1/22 ,  C07K14/705 ,  C07K16/00 ,  C07K16/28 ,  C12N15/02 ,  C12P21/00 ,  C12P21/08 ,  C12R1/91 ,  G01N33/53

Abstract: The present invention provides a substantially pure integrin characterized in that it consists of an alpha v and a beta 1 subunit. The receptor binds to fibronectin and GRGDSPK but does not bind to vitronectin. The alpha v beta 1 receptor can be used to determine the presence of ligands for the receptor.

公开(公告)号：AU633011B2

公开(公告)日：1993-01-21

申请号：AU3865389

申请日：1989-06-23

Applicant: LA JOLLA CANCER RESEARCH FOUNDATION

Inventor： ERKKI I. RUOSLAHTI ,  YU YAMAGUCHI

IPC: C12N15/09 ,  A61K38/00 ,  A61P9/10 ,  A61P13/02 ,  A61P13/12 ,  A61P15/00 ,  A61P19/02 ,  A61P29/00 ,  A61P35/00 ,  A61P43/00 ,  C07K1/22 ,  C07K14/00 ,  C07K14/47 ,  C07K14/50 ,  C12N5/00 ,  C12N5/02 ,  C12N5/06 ,  C12N5/10 ,  C12N15/12 ,  C12P21/00 ,  C12P21/02 ,  C12R1/91

Abstract: The present invention relates to the proteoglycan Decorin (also known as PG-II or PG-40). The invention provides cells transfected with and expressing a gene coding for Decorin. Spent culture media from such transfected cell cultures can be used to suppress the proliferation of either normal or abnormal cells. Purified Decorin can be used to suppress cell proliferation.